Vaccines the next regime change for markets

Christopher Joye

Coolabah Capital

In the AFR today I write that the next big pivot-point for markets in the months ahead will likely be the advent of vaccines. To read the full column click here or AFR subs can click here. Excerpt enclosed:

Since February we have argued the contrarian case that vaccines would arrive in 2020 well-ahead of consensus estimates, and that they would be cheap and broadly effective. Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and adviser to every US president since Ronald Reagan, was initially sceptical of this projection, arguing in early March that “it will take at least a year to a year in a half to have a vaccine we can use”.

Yet as a result of record public funding and support for COVID-19 vaccine research, Fauci has embraced a more optimistic assessment. Following the release this week of the results of the first human trial of Moderna’s vaccine, which triggered the desired immune response in all 45 people tested, Fauci declared that the US was on track to develop a vaccine before the end of the year. "I feel good about the projected timetable," Fauci said.

Crucially, Moderna has already started mass commercial production of its vaccine at three different plants across the US in anticipation of regulatory approval, and expects to be able to produce 500 million to one billion doses each year.

In total there are already 23 different COVID-19 vaccines in human trials globally, with six in, or about to start, final phase three trials, including programs in the US, China, Brazil and Russia.

There are nonetheless outstanding questions in relation to the efficacy of vaccines. We still don’t know how long the neutralising antibodies induced by them last for. It is entirely possible we will need to have regular updates, perhaps once a year. We also don’t know what proportion of patients the vaccine will actually protect. Dr Fauci says he would settle for a 70 to 75 per cent effectiveness rate.

The key for markets is that a vaccine will allow investors to finally see the light at the end of the tunnel. It will portend the world returning to some semblance of normality and almost certainly trigger another leg to the current risk rally.

In my own portfolios, I have been taking profits on the circa $1 billion of purchases we made in late February and March. In particular, I have net sold $937 million since the end of March, which almost exactly offsets our net investments in the months prior. We have, however, been more active than these numbers imply, buying and selling almost $9.2 billion of bonds since the start of 2020 with zero issues with liquidity.

The problems with liquidity in the corporate bond market in 2020 that folks have complained about have been limited to highly pro-cyclical assets that were always going to perform poorly in a recession like the current one. These include bonds issued by commercial property trusts, residential developers, retailers, airlines, and non-bank lenders that offer finance to riskier borrowers that cannot get approved via a normal bank.

Lots of investors loaded up on these credits in recent years to get access to the extra yield they pay. We avoided them because it was obvious that in any downturn liquidity for these superficially well-rated securities would disappear. In this sense, the diversification that a large portfolio of corporate bonds provided was a mirage: often investors were just loading up on correlated default and liquidity risks.

One asset we did pick-up last week was NAB’s new unlisted, or over-the-counter, hybrid, which paid a credit spread of 4 per cent above the quarterly bank bill swap rate (or a total running yield of about 4.1 per cent). That represented a chunky 0.50 per cent premium over the spread available on identical major bank hybrids on the ASX.

This investment-grade (or BBB- rated) hybrid was a landmark of sorts as the first OTC hybrid deal from a major bank in over a decade that was distributed widely via multiple brokers and banks. And it has since performed well with its spread compressing to about 3.88 per cent above bank bills, furnishing capital gains of about 50 basis points in its first week.

The most interesting development has, however, been the subsequent trading activity. With five different market-makers providing secondary liquidity, we have seen daily turnover in this single OTC hybrid that has been about 50 per cent of the entire ASX hybrid market.

While the ASX hybrid market will always have a role to play, banks are likely to shift at least some of their capital raising activities to the more sophisticated OTC domain. This is not negative for ASX hybrid holders because it presages a future scarcity premium for those who are limited to the listed market.

Never miss an update

Stay up to date with my content by hitting the 'follow' button below and you'll be notified every time I post a wire. Not already a Livewire member? Sign up today to get free access to investment ideas and strategies from Australia's leading investors.

General Disclaimer: Past performance does not assure future returns. All investments carry risks, including that the value of investments may vary, future returns may differ from past returns, and that your capital is not guaranteed. This information has been prepared by Coolabah Capital Investments Pty Ltd (ACN 153 327 872). It is general information only and is not intended to provide you with financial advice. You should not rely on any information herein in making any investment decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. The Product Disclosure Statement (PDS) for the funds should be considered before deciding whether to acquire or hold units in it. A PDS for these products can be obtained by visiting Neither Coolabah Capital Investments Pty Ltd, EQT Responsible Entity Services Ltd (ACN 101 103 011), Equity Trustees Ltd (ACN 004 031 298) nor their respective shareholders, directors and associated businesses assume any liability to investors in connection with any investment in the funds, or guarantees the performance of any obligations to investors, the performance of the funds or any particular rate of return. The repayment of capital is not guaranteed. Investments in the funds are not deposits or liabilities of any of the above-mentioned parties, nor of any Authorised Deposit-taking Institution. The funds are subject to investment risks, which could include delays in repayment and/or loss of income and capital invested. Past performance is not an indicator of nor assures any future returns or risks. Coolabah Capital Institutional Investments Pty Ltd holds Australian Financial Services Licence No. 482238. Forward-Looking Disclaimer: This information may contain some forward-looking statements. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Coolabah Capital Investments Pty Ltd undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to rely on forward-looking statements.

Portfolio Manager & Chief Investment Officer
Coolabah Capital

Chris co-founded Coolabah in 2011, which today runs over $8 billion with a team of 26 executives focussed on generating credit alpha from mispricings across fixed-income markets. In 2019, Chris was selected as one of FE fundinfo’s Top 10 “Alpha...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.